Vanderbilt University Medical Center: Atrial Fibrillation trials
The registry lists 10 Atrial Fibrillation studies with Vanderbilt University Medical Center as lead sponsor. 1 are open to participants now and 5 have results posted.
Phase 2 1Phase 4 2No phase 7(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Defining the Risk of Ventricular Tachycardia in Genetic CardiomyopathiesRecruitingNCT06575881
- 2-Hydroxybenzylamine (2-HOBA) to Prevent Early Recurrence of Atrial Fibrillation After Catheter-based AblationCompletedNCT04433091Phase 2Results posted
- Efficacy of Short Term Dabigatran Etexilate Followed by Aspirin Monotherapy After LAA (Left Atrial Appendage) Device Closure (the DEA-LAA Study).CompletedNCT03539055Phase 4Results posted
- Use of Dabigatran Etexilate to Prevent Stroke and ThromboembolismCompletedNCT01976507Phase 4Results posted
- Genetically Determined Response to Atenolol in Patients With Persistent Atrial FibrillationCompletedNCT01719367Not applicableResults posted
- ST-segment Elevation as an AF EndophenotypeCompletedNCT01205529Not applicableResults posted
- Defining the Risk of Ventricular Tachycardia in Genetic Forms of Early-onset Atrial FibrillationTerminatedNCT06647459
- Prospective Phenotyping for Genetic Subtypes of Early-onset Atrial FibrillationCompletedNCT05190679
- Preemptive Pharmacogenetic-guided Metoprolol Management for PostoperativeAtrial Fibrillation in Cardiac SurgeryCompletedNCT03943927Not applicable
- Peripheral Venous Analysis (PIVA) for Predicting Volume Responsiveness and Fluid StatusTerminatedNCT03407287